Completed PHASE3 INTERVENTIONAL 2-arm NCT00711646

A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.

A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.

Sponsor: Jazz Pharmaceuticals

Conditions Multiple Sclerosis Spasticity

Interventions Placebo Sativex®

Updated 7 times since 2017 Last updated: Apr 7, 2023 Started: Jun 30, 2002 Primary completion: Mar 31, 2004 Completion: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Multiple Sclerosis and Spasticity, this trial is completed. The trial is conducted by Jazz Pharmaceuticals and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2023 — Jul 2024 [monthly]

Completed PHASE3
Mar 2022 — Jun 2023 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jazz Pharmaceuticals

Data source: Jazz Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Reading, United Kingdom